57) Hairy cell leukemia
is positive for all common B-cell antigens (CD19, CD20, CD79a, FMC-7, and PAX5), with characteristic expression of annexin A1 (Figure 7, A), CD11c, CD25, CD103, CD123, DBA-44 (CD72) (Figure 7, B), the Hector Battifora mesothelial epitope-1 (HBME-1), pERK, Tbet, and TRAP58-61 but is typically negative for CD5 and CD10, although 10% to 20% of HCLs are positive for CD10.
The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia
MA (23%), leukemia (18%) (13 cases), hypoocellular marrow with no other specific finding (7%), aplastic anemia (3%), normocellular marrow with no specific finding (3%), Lymphoma (3%), leishmaniasis (3%), Hairy cell leukemia
(1%), MDS/MPN (1%), MMM (1%) and MM (1%).
A blood smear showed 10% hairy cells, and a bone marrow biopsy confirmed a diagnosis of hairy cell leukemia
and interstitial infiltration of CD20-positive, monoclonal antibody DBA.
Although the etiology of paraneoplastic vasculitis is not yet clearly known, suggested mechanisms are: (i) vascular damage caused by cross-reactions between antibodies against tumor cells and the vascular endothelium (ii) vascular inflammation caused by immune complexes involving tumor antigens (iii) direct vascular damage caused by the hairy cells in hairy cell leukemia
Symptoms of hairy cell leukemia
include fatigue, weakness, and weight loss.
However, the gene expression profile of the icukemic cells is not the same as that of the normal counterpart and displays many similarities and differences (7), (24-27) Gene expression profile of the leukemic B cells in fbllicular lymphorna, hairy cell leukemia
and CLL has been shown to resemble the germinal center or the memory stage of differentiati on (7), (24), (28), (29).
Pulmoanry legionellosis at the earliest stage of hairy cell leukemia
in the absence of a clonal marker, no evidence that the bone marrow fibrosis or other changes are secondary to infection, autoimmune disorder or other chronic inflammatory condition, hairy cell leukemia
or other lymphoid neoplasm, metastatic malignancy, or toxic myelopathies (1)
Cladribine is an antineoplastic agent that has been approved for the treatment of active hairy cell leukemia
Conditions covered include acute lymphoblastic leukemia, follicular lymphoma, nodal marginal zone lymphoma, and hairy cell leukemia
GCR-3888 has shown efficacy in a Phase I clinical trial and is currently in a Phase II clinical trial for the treatment of hairy cell leukemia